GlassScriptPhysician profile
Douglas E Neagles
NPI 1699727586
$3,864.00
in general payments reported to CMS, 2019-2025
31 companies · $40.06 in 2025
The $40.06 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $73.40 · 2022: $842 · 2023: $1,809 · 2024: $1,099 · 2025: $40.06.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,949.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,948.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $498.43 | 2021-2025 | |
| Lilly USA, LLC | $409.39 | 2022-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $287.65 | 2022-2024 | Ozempic, Rybelsus |
| Esperion Therapeutics, INC. | $259.43 | 2022-2024 | Nexletol |
| Amgen INC. | $245.30 | 2022-2024 | Repatha, Otezla, Prolia |
| Glaxosmithkline, LLC. | $230.55 | 2021-2024 | Trelegy Ellipta, Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $214.27 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.21 | 2022-2024 | Jardiance, Synjardy, Stiolto Respimat |
| Boston Scientific Corporation | $187.13 | 2023-2024 | Watchman Flx |
| Sanofi-Aventis U.S. LLC | $182.37 | 2022-2023 | |
| E.R. Squibb & Sons, L.L.C. | $165.93 | 2022-2024 | Eliquis, Camzyos |
| Xeris Pharmaceuticals, INC. | $145.17 | 2022-2024 | Gvoke Hypopen |
| Radius Health, INC. | $105.33 | 2023-2024 | Tymlos |
| Pfizer INC. | $97.08 | 2022-2023 | |
| Vanda Pharmaceuticals INC. | $79.80 | 2022-2023 | Hetlioz |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $67.48 | 2022-2023 | Steglatro, Belsomra, Lagevrio |
| Novartis Pharmaceuticals Corporation | $65.11 | 2023-2024 | |
| Astellas Pharma US INC | $63.99 | 2024 | Veozah |
| Almatica Pharma LLC | $48.18 | 2022-2023 | Loreev Xr, Sertraline Hcl, Gralise |
| Dexcom, INC. | $43.60 | 2023-2024 | Dexcom G6 Transmitter |
| Kowa Pharmaceuticals America, INC. | $38.44 | 2022 | |
| Antares Pharma, INC. | $37.17 | 2023 | Nocdurna, Tlando, Xyosted |
| Idorsia Pharmaceuticals US INC | $32.94 | 2023-2024 | Quviviq |
| Astrazeneca Pharmaceuticals LP | $28.93 | 2024 | Airsupra, Farxiga |
| Abbott Laboratories | $26.42 | 2023 | Freestyle Libre 2 |
| Phathom Pharmaceuticals, INC. | $20.18 | 2024 | Voquezna |
| Corcept Therapeutics | $20.03 | 2023 | Korlym |
| Halozyme INC | $17.18 | 2023 | |
| Janssen Pharmaceuticals, INC | $15.22 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $15.05 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $13.04 | 2023 | Evkeeza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Neagles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.